S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Y-mAbs Therapeutics Stock Forecast, Price & News

-0.77 (-7.01%)
(As of 01/21/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
556,362 shs
Average Volume
346,319 shs
Market Capitalization
$446.04 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive YMAB News and Ratings via Email

Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Y-mAbs Therapeutics logo

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$20.75 million
Book Value
$2.61 per share


Net Income
$-119.34 million
Pretax Margin




Free Float
Market Cap
$446.04 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.47 out of 5 stars

Medical Sector

149th out of 1,418 stocks

Pharmaceutical Preparations Industry

61st out of 684 stocks

Analyst Opinion: 3.3Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -

Y-mAbs Therapeutics (NASDAQ:YMAB) Frequently Asked Questions

Is Y-mAbs Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Y-mAbs Therapeutics stock.
View analyst ratings for Y-mAbs Therapeutics
or view top-rated stocks.

How has Y-mAbs Therapeutics' stock price been impacted by COVID-19?

Y-mAbs Therapeutics' stock was trading at $22.98 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, YMAB stock has decreased by 55.5% and is now trading at $10.22.
View which stocks have been most impacted by COVID-19

When is Y-mAbs Therapeutics' next earnings date?

Y-mAbs Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Y-mAbs Therapeutics

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) issued its earnings results on Thursday, November, 4th. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by $0.08. The business earned $8.97 million during the quarter, compared to the consensus estimate of $10.87 million. Y-mAbs Therapeutics had a negative trailing twelve-month return on equity of 19.08% and a negative net margin of 83.21%. During the same quarter last year, the company earned ($0.82) EPS.
View Y-mAbs Therapeutics' earnings history

What price target have analysts set for YMAB?

5 brokers have issued 1 year price targets for Y-mAbs Therapeutics' stock. Their forecasts range from $25.00 to $68.00. On average, they expect Y-mAbs Therapeutics' stock price to reach $43.00 in the next twelve months. This suggests a possible upside of 320.7% from the stock's current price.
View analysts' price targets for Y-mAbs Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Y-mAbs Therapeutics' key executives?

Y-mAbs Therapeutics' management team includes the following people:
  • Thomas Gad, Chairman, President & Head-Business Development
  • Claus Juan Møller-San Pedro, Director, Chief Executive & Commercial Officer
  • Joris Wiel Jan Wilms, Chief Operating Officer & Senior Vice President
  • Bo Kruse, CFO, Secretary. Treasurer & Executive VP (LinkedIn Profile)
  • Torben Lund-Hansen, Chief Technology Officer & Senior Vice President

What other stocks do shareholders of Y-mAbs Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN).

When did Y-mAbs Therapeutics IPO?

(YMAB) raised $80 million in an initial public offering on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

What is Y-mAbs Therapeutics' stock symbol?

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

Who are Y-mAbs Therapeutics' major shareholders?

Y-mAbs Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Russell Investments Group Ltd. (0.15%) and DNB Asset Management AS (0.03%). Company insiders that own Y-mAbs Therapeutics stock include Biotech Aps Wg, Bo Kruse, David N Gill, Johan Wedell-Wedellsborg, Mahiuddin Ahmed, Pedro Claus Juan Moller-San, Thomas Gad and Vignesh Rajah.
View institutional ownership trends for Y-mAbs Therapeutics

Which major investors are buying Y-mAbs Therapeutics stock?

YMAB stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., and DNB Asset Management AS. Company insiders that have bought Y-mAbs Therapeutics stock in the last two years include Pedro Claus Juan Moller-San, and Vignesh Rajah.
View insider buying and selling activity for Y-mAbs Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Y-mAbs Therapeutics' stock price today?

One share of YMAB stock can currently be purchased for approximately $10.22.

How much money does Y-mAbs Therapeutics make?

Y-mAbs Therapeutics has a market capitalization of $446.04 million and generates $20.75 million in revenue each year. The company earns $-119.34 million in net income (profit) each year or ($0.93) on an earnings per share basis.

How many employees does Y-mAbs Therapeutics have?

Y-mAbs Therapeutics employs 125 workers across the globe.

What is Y-mAbs Therapeutics' official website?

The official website for Y-mAbs Therapeutics is www.ymabs.com.

Where are Y-mAbs Therapeutics' headquarters?

Y-mAbs Therapeutics is headquartered at 230 Park Avenue Suite 3350, NEW YORK NY, 10169.

How can I contact Y-mAbs Therapeutics?

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company can be reached via phone at (646) 885-8505 or via email at [email protected].

This page was last updated on 1/23/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.